Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Liz Lewis

KEYNOTE PRESENTATION: Building Value Through External Stakeholder Engagement

Takeda Oncology

7:30am 8:00am (30 mins)

Main agenda

Breakfast & Technology Workshop: Addressing the Risk of Bioburden and the Need for Increased Productivity in Protein A Chromatography

Please note: The exhibit hall is not open following this talk. The exhibit hall opens today at 10:20am

Historically, the alkali stability of Protein A chromatography resins has lagged behind other resins used in downstream purification of antibody therapeutics. This fact, combined with the high nutrient load to which Protein A resins are exposed, introduces a larger risk of column contamination when compared with secondary and tertiary chromatographic operations. In this presentation, we present a newly designed protein A resin which offers alkali stability on par with ion exchange and hydrophobic interaction chromatography resins. Data on binding capacity, caustic stability and resin cleanability will be presented.

  • Jonathan Royce - Business Leader - Chromatography Resins, GE HealthCare Life Sciences

9:50am 10:20am (30 mins)

Technology Workshop

Bioseparation Media by Mitsubishi Chemical

Brought to you by BPI Sponsor: Mitsubishi Chemical

For >70 years Mitsubishi Chemical has been manufacturing industrial separation media for peptides and small to large molecules. Our newest media, MabSpeed™(protein A) and ChromSpeed™ (ion exchange) are specially designed for purification of biopharmaceuticals (antibody-drugs, protein-drugs, etc.) as well as large oligonucleotides for high throughput processing. The details of these products will be introduced during the seminar.

  • Mayumi Kiyono-Shimobe, Ph.D. - Business Development Manager, Separation Materials Department, Mitsubishi Chemical America, Inc.

9:50am 10:20am (30 mins)

Technology Workshop

Thirty Years of mAbs and Protein A: A Retrospective Look at 30 Years of Synergies

Brought to you by BPI Sponsor: GE Healthcare

Thirty years ago, monoclonal antibodies were mainly research projects which were barely represented in pharmaceutical sales. Today, mAbs represent 50% of all biological sales and the pipeline of future mAbs and other antibody constructs is rich. Dr. Hale, who was involved in the development of one of the first mAbs, Campath, will look back on the dramatic success of our industry and how the developments of antibody and protein A technologies have followed a synergistic path to bring the industry to its current state.

  • Geoff Hale, Ph.D. - Director, Absolute Antibody Ltd

9:50am 10:20am (30 mins)

Technology Workshop

Solutions for Maximizing Binding Capacity of Intact mAb and mAb Fragments Purification with Minimal Impurity Levels

Protein A and Protein L chromatography resins are used as a capture step for intact mAbs, antibody fusion proteins and mAb fragments.  Because of their unique specificity, these resins are capable of adequately removing most process impurities.  They also exhibit the highest binding capacity, the widest range of mAb subclass specificity and are resistant to alkaline cleaning.

  • J. Kevin O'Donnell, Ph.D. - Process Chromatography Support Manager, Tosoh Bioscience LLC

9:50am 10:20am (30 mins)

Technology Workshop

Monitoring and Controlling Viable Biomass in Bioprocesses Using Dielectric Spectroscopy for PAT Control

The radio-frequency impedance method for real time detection of viable biomass is established in biopharmaceutical applications. This method provides real time information of live biomass and is used extensively to monitor processes and make process decisions. This presentation covers the principle behind the impedance method, its benefits, and applications of the technology across processes, making it a robust PAT tool.

  • Aditya Bhat, Ph.D. - Director of Technology, Aber Instruments, Inc.

9:50am 10:20am (30 mins)

Technology Workshop

Overcoming Validation Challenges in a Single-Use World

The presentation panel discusses the three perspectives (bioprocessing company, system integrator, component manufacturer) of validation methodology for single-use systems as the bioprocessing industry is confronted with producing safe therapies and vaccines while meeting government regulations and constant pressure to lower cost per dose. It takes a look at the challenges in implementation and adoption of validation methodology and the benefits of collaboration.

  • Derek Pendlebury, Ph.D. - OEM Channel Manager, Bioproccessing, CPC - Colder Products Company

10:20am 11:00am (40 mins)

Main agenda

Refreshment Break in the BWB Poster & Exhibit Hall

10:30am 11:30am (60 mins)

Main agenda

Correspondents Panel Discussion: State of the Life Sciences 2018 and Views on the Landscape Ahead


Alex de Winter, Managing Director, GE Ventures


Alex Lash, National, Biotechnology Editor, Xconomy

Luke Timmerman, Founder and Editor, Timmerman Report

Rebecca Robbins, Business Reporter, STAT News

  • Panelist Alex Lash - National Biotechnology Editor, Xconomy
  • Panelist Luke Timmerman - Founder and Editor, Timmerman Report
  • Panelist Rebecca Robbins - Business Reporter, STAT News
  • Moderator Alex de Winter - Managing Director, GE Ventures

12:00pm 1:00pm (60 mins)

Mass BIO CRO/CMO Symposium

Registration and Lunch

1:00pm 2:00pm (60 mins)

Mass BIO CRO/CMO Symposium

Opening Remarks & Panel Discussion: Different Perspectives on Acquisitions: Vendors & Sponsors Evaluate the Pros and Cons

While it is somewhat common for established pharma and biotech companies to acquire CROs, industry professionals have different perspectives on the subject. When is consolidation the right choice for companies and how does this affect the company and industry landscape? Representatives from both vendor and sponsor companies will share their experiences in consolidations, the challenges and benefits, and risk and reward.

  • Peter Meltzer, CEO, Organix
  • EVan Guggenheim, Biogen (Moderator)

And additional expert speakers from small & large biotech, pharma and CRO/CMO companies

2:00pm 2:45pm (45 mins)

Mass BIO CRO/CMO Symposium

Breakout/Roundtable Sessions 1

  • The Responsive Vendor: Developing Strong Sponsor-CRO Relationships
    • Stacey Lindey, QuintilesIMS
  • Minimizing Risk in Outsourcing: How to Benefit from an Enhanced Integrated Preclinical Program
    • Sam Chuang, Charles River Labs
    • Keith Giza, Principal Research Associate Scientist, Moderna Therapeutics
    • Damon Demady, Director of Toxicology, Mersana
  • Partnerships, Global vs. Local: Finding the Right Sourcing Partner
  • Sourcing for Start-ups and Early Stage Firms

3:15pm 4:00pm (45 mins)

Mass BIO CRO/CMO Symposium

Breakout/Roundtable Sessions 2

  • Workshop
    • Don Dickison, Juniper Therapeutics
  • New Platforms: Eliminating Administrative Friction in Outsourcing
    • Mary Kachinsky, Vice President, Strategic Sourcing and Operations, Forma
  • From Startup to Second Stage
    • Gerry Cox, Chief Operating Officer, Velesco Pharma
  • Global Manufacturing 
  • Managing a Complex CMO Network

4:00pm 5:00pm (60 mins)

Mass BIO CRO/CMO Symposium

Closing Panel: Relationships: Sponsors, Consultants and CROs & CMOs

The relationships between sponsors, consultants and CROs & CMOs are becoming increasingly complex, as more companies, both large and small, interface with consultants. How do companies effectively manage relationships, ensuring seamless communications between sponsoring companies, service providers and consultants? How can you strike a balance between micromanaging these relationships and offering full autonomy? When is it appropriate to engage outside consultants, and what is the proper way to navigate the partnerships?

  • Wes Westlin, Senior Vice President, Preclinical Research & Early Development, Nimbus Discovery
  • Jeff Saunders, Co-founder, JOSC LLC
  • Michael Settles, Owner, TGA Biosciences
  • Colin Minchom (Moderator)

5:00pm 6:00pm (60 mins)

Mass BIO CRO/CMO Symposium

Cocktail Reception

12:30pm 1:15pm (45 mins)

Main agenda

Networking Luncheon in the BWB Poster & Exhibit Hall

1:15pm 1:20pm (5 mins)

Main agenda

Chairperson's Remarks

  • Robert Coughlin - President and CEO, MassBio

1:20pm 2:00pm (40 mins)

Main agenda

KEYNOTE PRESENTATION: Building Value Through External Stakeholder Engagement

  • Liz Lewis - Chief Counsel and Head of Patient Advocacy, Takeda Oncology

2:00pm 2:15pm (15 mins)

Main agenda

BWB Passport Prizes Announced from Keynote Stage

2:15pm 2:15pm (0 mins)

Main agenda

Close of Conference and BWB Poster & Exhibit Hall